<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335035">
  <stage>Registered</stage>
  <submitdate>16/01/2010</submitdate>
  <approvaldate>20/01/2010</approvaldate>
  <actrnumber>ACTRN12610000066088</actrnumber>
  <trial_identification>
    <studytitle>Treatment of Lentigo Maligna with imiquimod 5% cream.</studytitle>
    <scientifictitle>Treatment of Lentigo Maligna by imiquimod 5% cream as assessed by pathological assessment of the surgical excison specimen of the complete treated area</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lentigo maligna</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>imiquimod 5% cream masaged directly into the lentigo maligna each day from Monday to Friday with breaks from treatment on Saturday and Sunday and any other day when the inflammation due to the cream is intolerable. This is done for 12 weeks.</interventions>
    <comparator>nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>clearance of lentigo maligna as demonstrated by histological assessment of the complete surgical excison specimen of the entire treated area post application of imiquimod</outcome>
      <timepoint>after the 12 weeks of imiquimod application an assessment is made and surgery is scheduled within the next 2 weeks depending on the expected time for the inflammation to settle as determined by the investigators</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>pathologist concordance in assessment of specimens</outcome>
      <timepoint>post surgical excision</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>relevance of inflammatory reaction to clearance of tumour as assessed by clinical review of the inflammatory reaction severity graded as none,  mild , moderate or severe.</outcome>
      <timepoint>post surgical excision</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>lentigo maligna greater than 5mm diiameter</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>detection of invasive melanoma</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>full consent procedure for all eligible patients</concealment>
    <sequence>noot randomized</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>use of two pathologists independently assessing diagnostic and end point specimens</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/01/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Alfred Hospital</primarysponsorname>
    <primarysponsoraddress>Commercial Road
Prahran
Victoria 3181</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Victorian Melanoma Service</fundingname>
      <fundingaddress>Alfred Hospital 
Commercial road 
Prahran
Victoria 3181</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>iNova</sponsorname>
      <sponsoraddress>9-15 Chilvers Road
Thornleigh
New South  Wales 2120</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of the study is to determine how effective imiquimod cream is in curing lentigo maligna and whether it is a possible replacement for surgical excison as the primary treatment.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>Commercial Road
Prahran
Victoria 3181</ethicaddress>
      <ethicapprovaldate>17/12/2005</ethicapprovaldate>
      <hrec>1/05/0174</hrec>
      <ethicsubmitdate>1/06/2005</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Martin Haskett</name>
      <address>PO Box 7293
Karingal Centre
Victoria 3199</address>
      <phone>613 9770 9788</phone>
      <fax>613 9770 9755</fax>
      <email>mhaskett@haskettderm.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Martin Haskett</name>
      <address>PO Box 7239
Karingal Centre
Vicotria 3199</address>
      <phone>613 9770 9788</phone>
      <fax>613 9770 9755</fax>
      <email>mhaskett@haskettderm.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>